云南白药
(000538)
| 流通市值：951.74亿 | | | 总市值：957.91亿 |
| 流通股本：17.85亿 | | | 总股本：17.97亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 39,111,292,156 | 29,688,532,074.44 | 20,309,372,850.07 | 10,512,750,996.14 |
| 营业收入 | 39,111,292,156 | 29,688,532,074.44 | 20,309,372,850.07 | 10,512,750,996.14 |
| 二、营业总成本 | 35,082,749,923.97 | 25,655,346,434.64 | 17,462,566,820.49 | 9,079,602,330.72 |
| 营业成本 | 28,744,517,640.29 | 21,561,766,815.34 | 14,713,232,267.4 | 7,630,142,609.46 |
| 税金及附加 | 210,801,478.72 | 156,679,835.57 | 108,372,830.01 | 47,905,768.36 |
| 销售费用 | 4,992,157,591.11 | 3,354,092,495.64 | 2,257,688,549.69 | 1,200,761,671.98 |
| 管理费用 | 1,058,503,523.9 | 555,447,083.84 | 344,443,810.4 | 164,475,030.95 |
| 研发费用 | 336,013,434.83 | 218,605,959.51 | 144,819,933.66 | 64,085,946.58 |
| 财务费用 | -259,243,744.88 | -191,245,755.26 | -105,990,570.67 | -27,768,696.61 |
| 其中:利息费用 | 49,601,252.93 | 25,659,659.41 | 18,798,896.05 | 10,370,907.6 |
| 其中:利息收入 | 315,758,812.17 | 207,456,606.36 | 114,776,796.46 | 51,493,712.34 |
| 加:公允价值变动收益 | 123,566,330.46 | 103,647,141.05 | 53,088,928.07 | 103,152,130.15 |
| 加:投资收益 | 779,010,728.82 | 703,223,493.07 | 421,542,165.56 | 242,399,008.29 |
| 资产处置收益 | 10,654,438.38 | 5,480,553.14 | 5,403,078.51 | -1,342,038.47 |
| 资产减值损失(新) | -58,127,562.23 | 12,991,451.24 | 19,008,334.9 | 5,068,315.53 |
| 信用减值损失(新) | -136,455,204.36 | -100,065,150.07 | -74,680,582.29 | -74,081,103.14 |
| 其他收益 | 83,315,147.32 | 114,914,121.46 | 42,177,454.66 | 21,835,747.77 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 4,830,506,110.42 | 4,873,377,249.69 | 3,313,345,408.99 | 1,730,180,725.55 |
| 加:营业外收入 | 12,234,049.26 | 5,676,695.44 | 2,002,724.29 | 2,636,560.95 |
| 减:营业外支出 | 24,728,403.02 | 15,290,657.04 | 12,068,474.23 | 5,664,180.4 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 4,818,011,756.66 | 4,863,763,288.09 | 3,303,279,659.05 | 1,727,153,106.1 |
| 减:所得税费用 | 695,450,660.17 | 741,257,264.53 | 477,020,837.61 | 211,429,634.21 |
| 六、净利润 | 4,122,561,096.49 | 4,122,506,023.56 | 2,826,258,821.44 | 1,515,723,471.89 |
| 持续经营净利润 | 4,122,561,096.49 | 4,122,506,023.56 | 2,826,258,821.44 | 1,515,723,471.89 |
| 归属于母公司股东的净利润 | 4,093,782,074.02 | 4,123,477,414.45 | 2,828,011,615.3 | 1,517,988,356.56 |
| 少数股东损益 | 28,779,022.47 | -971,390.89 | -1,752,793.86 | -2,264,884.67 |
| (一)基本每股收益 | 2.29 | 2.31 | 1.58 | 0.85 |
| (二)稀释每股收益 | 2.29 | 2.3 | 1.58 | 0.85 |
| 八、其他综合收益 | -21,847,821.78 | -27,756,402.56 | -28,749,435.38 | 6,561,595.3 |
| 归属于母公司股东的其他综合收益 | -21,450,521.18 | -32,077,219.63 | -27,537,362.56 | 4,785,778.46 |
| 九、综合收益总额 | 4,100,713,274.71 | 4,094,749,621 | 2,797,509,386.06 | 1,522,285,067.19 |
| 归属于母公司股东的综合收益总额 | 4,072,331,552.84 | 4,091,400,194.82 | 2,800,474,252.74 | 1,522,774,135.02 |
| 归属于少数股东的综合收益总额 | 28,381,721.87 | 3,349,426.18 | -2,964,866.68 | -489,067.83 |
| 公告日期 | 2024-03-30 | 2023-10-31 | 2023-08-30 | 2023-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |